Health Care • Biotechnology: Pharmaceutical Preparations
$1.22 ▲ +0.00
(0.00%)
MKT CAP: $152.4M • VOL: 422.2K
52W L $1 52W H $3
ROARABLE / RQD
D • 50/100
PIOTROSKI
4 / 9
ALXO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$104.0M | -$142.5M | -$170.3M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$101.7M | -$134.8M | -$160.8M |
| EBITDA (Normalized) | -$103.9M | -$142.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$84.1M | -$121.9M | -$130.4M |
| Capital Expenditures (CapEx) | $212.0K | $447.0K | — |
| Free Cash Flow (FCF) | -$84.4M | -$122.4M | -$130.4M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $16.4M | $17.6M | — |
| Total Debt (Short + Long Term) | $4.5M | $9.5M | — |
| Total Stockholders' Equity | $26.0M | $113.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ALXO.